Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs LEUCOVORIN CALCIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Leucovorin calcium is a reduced form of folic acid that serves as a cofactor in nucleic acid synthesis. It is converted to tetrahydrofolate (THF), which is essential for purine and pyrimidine biosynthesis. It bypasses dihydrofolate reductase (DHFR), allowing continued DNA synthesis in the presence of methotrexate or other DHFR inhibitors.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Rescue therapy after high-dose methotrexate in osteosarcoma,To diminish the toxicity and counteract the effects of impaired methotrexate elimination,Treatment of megaloblastic anemias due to folic acid deficiency,In combination with 5-fluorouracil in colorectal cancer (off-label)
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
15 mg orally, intramuscularly, or intravenously every 6 hours for 5 to 7 doses; for rescue after high-dose methotrexate: 10 mg/m2 every 6 hours until serum methotrexate level <5×10^-8 M; for advanced colorectal cancer: 200 mg/m2 IV over 2 hours with 5-fluorouracil 370 mg/m2 IV bolus on days 1-5 every 28 days.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Leucovorin (5-formyltetrahydrofolate) has a terminal half-life of approximately 6.2 hours for the active [6S]-isomer and 31-33 hours for the inactive [6R]-isomer. The active metabolite, 5-methyltetrahydrofolate, has a half-life of about 3.5 hours. Clinical context: Half-life is dose-dependent and prolonged in renal impairment.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Primarily hepatic and intracellular metabolism to active folate forms (e.g., 5-methyltetrahydrofolate).
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Primarily excreted in urine as inactive metabolites (80-90%) and unchanged drug (<5%). Fecal excretion accounts for 5-10% via biliary elimination of metabolites.
38-45%, primarily bound to albumin.
Leucovorin is approximately 15-20% bound to plasma proteins, primarily albumin. The active metabolite 5-methyltetrahydrofolate has higher binding (30-40% to albumin).
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Volume of distribution is 0.4-0.8 L/kg, indicating distribution into total body water. Clinical meaning: Leucovorin distributes widely to tissues including liver and kidneys; does not readily cross intact blood-brain barrier.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral: 90-100% absorbed (saturable at high doses). Intramuscular: 100% bioavailability. Intravenous: 100%.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl <20 m L/min) as methotrexate clearance is impaired; monitor methotrexate levels and adjust leucovorin dose accordingly.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential for altered folate metabolism; monitor for toxicity.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
For methotrexate rescue: 15 mg/m2 orally or intravenously every 6 hours for 5 to 7 doses; or 10 mg/m2 every 6 hours until serum methotrexate level <5×10^-8 M. For advanced colorectal cancer: 200 mg/m2 IV over 2 hours with 5-fluorouracil; dose adjustment based on body surface area.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
No specific age-related dose adjustments; use standard adult dosing with caution due to increased risk of renal and hepatic impairment; monitor methotrexate levels and adjust leucovorin dose as needed.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Because of the potential danger of intrathecal administration (which can be fatal), leucovorin calcium should not be given intrathecally. Also, accidental overdose of folic acid (including leucovorin) may obscure pernicious anemia and lead to irreversible neurological damage.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Monitor for severe allergic reactions, including anaphylaxis.,Caution in patients with pernicious anemia or other vitamin B12 deficiencies as it may mask hematologic signs while neurologic symptoms progress.,Leucovorin enhances the toxicity of 5-fluorouracil, especially in elderly patients; careful monitoring required.,Should not be administered intrathecally due to risk of severe adverse reactions or death.,Use with caution in patients with seizures or epilepsy.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to leucovorin or any component of the formulation,Pernicious anemia or other megaloblastic anemias due to vitamin B12 deficiency (unless used adjunctively with B12),Intrathecal administration
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
No significant food interactions reported. However, because leucovorin is often used with methotrexate, patients should avoid alcohol (increases hepatotoxicity) and maintain adequate hydration.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
Leucovorin is a folate analog and is not teratogenic at therapeutic doses. Data from animal studies and human pregnancies show no increased risk of major birth defects. However, high doses may interfere with folate metabolism, but no specific adverse fetal effects have been documented. Use during pregnancy is considered low risk.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Leucovorin is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is not well established, but due to its low molecular weight, transfer is likely. No adverse effects in breastfed infants have been reported. Use with caution, weighing benefits against risks.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
Pregnancy may alter leucovorin pharmacokinetics due to increased plasma volume and renal clearance, but no specific dose adjustments are recommended. Dosing should be based on the indication (e.g., methotrexate rescue) and clinical response. Monitor as appropriate.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Leucovorin calcium is used as a rescue agent after high-dose methotrexate therapy to prevent myelosuppression and mucositis. It must be initiated within 24 hours of methotrexate administration. Monitor serum methotrexate levels and renal function during rescue. Also used to enhance the efficacy of 5-fluorouracil in colorectal cancer by stabilizing the 5-FU-thymidylate synthase complex.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take leucovorin exactly as prescribed; do not miss doses.,If you miss a dose, contact your healthcare provider immediately.,Report any signs of allergic reaction (rash, hives, swelling, difficulty breathing).,You may need frequent blood tests to monitor methotrexate levels and kidney function.,Avoid alcohol and limit caffeine intake as they may worsen side effects.,Use effective contraception during treatment and for at least 1 month after the last dose.
No interactions on record
"The risk or severity of adverse effects can be increased when Leucovorin is combined with Capecitabine."
"The therapeutic efficacy of Raltitrexed can be decreased when used in combination with Leucovorin."
"The risk or severity of adverse effects can be increased when Leucovorin is combined with Fluorouracil."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs LEUCOVORIN CALCIUM, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. LEUCOVORIN CALCIUM is a Antidote (Folate Analog) that works by Leucovorin calcium is a reduced form of folic acid that serves as a cofactor in nucleic acid synthesis. It is converted to tetrahydrofolate (THF), which is essential for purine and pyrimidine biosynthesis. It bypasses dihydrofolate reductase (DHFR), allowing continued DNA synthesis in the presence of methotrexate or other DHFR inhibitors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and LEUCOVORIN CALCIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of LEUCOVORIN CALCIUM is: 15 mg orally, intramuscularly, or intravenously every 6 hours for 5 to 7 doses; for rescue after high-dose methotrexate: 10 mg/m2 every 6 hours until serum methotrexate level <5×10^-8 M; for advanced colorectal cancer: 200 mg/m2 IV over 2 hours with 5-fluorouracil 370 mg/m2 IV bolus on days 1-5 every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and LEUCOVORIN CALCIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. LEUCOVORIN CALCIUM is classified as Category C. Leucovorin is a folate analog and is not teratogenic at therapeutic doses. Data from animal studies and human pregnancies show no increased risk of major birth defects. However, hi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.